Who is the CEO of IMV Inc.?

Mr. Andrew Hall M.Sc. is a business executive who currently serves as the CEO of IMV Inc..

What is the Revenue Growth of IMV Inc.?

Revenue growth data for IMV Inc. is currently unavailable.

What is IMV Inc. operating Margin?

IMV Inc. operating margin is 0.00% which shows how much profit IMV.TO earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does IMV Inc. operate?

IMV Inc. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is IMV Inc. revenue growth?

Revenue growth data for IMV Inc. is currently unavailable.

IMV Inc.

IMV.TO•TSX

HealthcareBiotechnology

$1.12

$0.00(0.00%)

IMV Inc. (IMV.TO) Stock Overview

Explore IMV Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for IMV.TOStats details for IMV.TO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for IMV.TOAnalyst Recommendations details for IMV.TO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

CEO

Mr. Andrew Hall M.Sc.

Employees

Headquarters

130 Eileen Stubbs Avenue, Dartmouth, NS

Founded

2007